Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Jul 29, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$4.67B
sum of reported positions
Reported positions
32
Changes vs prior quarter
31
6 new · 9 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 78 measured positions in 8 quarters, the typical new or larger position finished −0.4 pts against the S&P 500 and 50% finished ahead of it. For scale, across all 503 funds with a result: −2.1 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
804 institutions report a stake; Lingotto Investment Management LLP is the #17 holder.
Also among the 20 largest: Capital Research Global Investors, Capital International Investors, Capital World Investors
599 institutions report a stake; Lingotto Investment Management LLP is the #5 holder.
Also among the 20 largest: Capital World Investors, Capital Research Global Investors
| Company | Shares | Value | Weight | Of company |
|---|---|---|---|---|
TEVA PHARMACEUTICAL INDS LTD | $685M | 14.7% | — | |
| $611M | 13.1% | 0.84% | ||
| $574M | 12.3% | 4.8% | ||
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
In its latest 13F, with holdings as of Jun 30, 2026 (Q2 2026), Lingotto Investment Management LLP reported 32 positions worth $4.67B. The largest: TEVA PHARMACEUTICAL INDS LTD, 14.7%; Carvana (CVNA), 13.1%; Molina Healthcare (MOH), 12.3%; Paramount Skydance Corporation (PSKY), 9.8%; Range Resources (RRC), 8.8%. The five largest make up 59% of the reported portfolio.
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $5.06B | $4.67B |
| Positions | 35 | 32 |
| Biggest line | — | TEVA PHARMACEUTICAL INDS LTD 15% |
535 institutions report a stake; Lingotto Investment Management LLP is the #1 holder.
Also among the 20 largest: Pentwater Capital Management LP, Slate Path Capital LP, Kohlberg Kravis Roberts & Co. L.P.
540 institutions report a stake; Lingotto Investment Management LLP is the #6 holder.
Also among the 20 largest: Orbis Allan Gray Ltd, Canoe Financial LP, Fuller & Thaler Asset Management, Inc.
110 institutions report a stake; Lingotto Investment Management LLP is the #1 holder.
1,690 institutions report a stake.
Also among the 20 largest: Capital World Investors

| $456M |
| 9.8% |
| 4.3% |
| $411M | 8.8% | 4.7% |
| $275M | 5.9% | 0.28% |
| $206M | 4.4% | 0.30% |
| $188M | 4.0% | 7.2% |
| $175M | 3.8% | 3.5% |
| $162M | 3.5% | 0.67% |
| $147M | 3.2% | 0.00% |
| $134M | 2.9% | 0.00% |
| $90.5M | 1.9% | 1.1% |
| $82M | 1.8% | 0.78% |
| $73.6M | 1.6% | 0.08% |
| $66.3M | 1.4% | 0.49% |
| $56.8M | 1.2% | — |
| $53.5M | 1.1% | 0.19% |
| $40.8M | 0.9% | 0.05% |
| $29.5M | 0.6% | 0.00% |
| $26.4M | 0.6% | 1.4% |
| $21.5M | 0.5% | 0.24% |
| $19.8M | 0.4% | 0.01% |
SchlumbergerCALL | $19.1M | 0.4% | — |
| $14.7M | 0.3% | 0.17% |
VANECK ETF TRUST
1.99M shares in Q1 2026
ServiceNow (NOW)
390K shares in Q1 2026
APi Group (APG)
307K shares in Q1 2026
Blue Owl Capital (OWL)
239K shares in Q1 2026
Rocket Companies (RKT)
178K shares in Q1 2026
Amazon (AMZN)
42K shares in Q1 2026
KKR & Co. (KKR)
27K shares in Q1 2026
Alibaba Group Holding (BABA)
17K shares in Q1 2026
Microsoft (MSFT)
13K shares in Q1 2026
TEVA PHARMACEUTICAL INDS LTD: $685M, or 14.7% of the portfolio reported for Q2 2026.
Between its last two 13F reports, Lingotto Investment Management LLP opened 6 new positions, added to 5, trimmed 11 and sold out of 9. The comparison is in share counts, so a price move alone does not count as buying or selling.
Its 13F for Q2 2026 adds up to $4.67B. That is not the whole firm: a 13F lists only US-listed shares and some options held at the end of the quarter, and leaves out cash, bonds, short positions and foreign holdings.
The report for Q2 2026 was filed on Jul 29, 2026. A manager has 45 days after the end of each quarter to file, so the holdings are always several weeks old when they become public.
On 78 positions it reported as new or larger over 8 quarters, the typical one finished −0.4 points against the S&P 500 after 90 days, and 50% finished ahead of it. Measured from the day each filing became public; history, not a forecast.
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.